Robert Leibel
Family Medicine · Superior, NENPI 1578540126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Amgen at 26.4% of the total. Reporting peaked in 2022 at $700 and has fallen 97.9% since, to $14 in 2024.
Across 141 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$513
- AbbVie$417
- Pfizer$253
- Otsuka America Pharmaceutical, Inc.$170
- Novo Nordisk$139
- Johnson & Johnson$77
- plus $373 from 16 others
What the payments were for
- Food & beverage$1,942100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $513 |
| AbbVie(2 entities) | 26 | $417 |
| Pfizer | 25 | $253 |
| Otsuka America Pharmaceutical, Inc. | 9 | $170 |
| Novo Nordisk | 10 | $139 |
| Johnson & Johnson | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 4 | $52 |
| AstraZeneca | 3 | $35 |
| BTG International Inc. | 2 | $33 |
| Novartis | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Lilly USA, LLC | 2 | $26 |
| Smith+Nephew | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Osiris Therapeutics Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Biocryst US Sales Co., LLC | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$1,942 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $4,293 |
| Atorvastatin Calcium | 18 | $201 |
| Montelukast Sodium | 14 | $169 |
| Tamsulosin Hcl | 13 | $154 |
| Losartan Potassium | 16 | $140 |
| Amlodipine Besylate | 20 | $135 |
| Levothyroxine Sodium | 11 | $115 |
| Furosemide | 32 | $103 |
| ClopidogrelClopidogrel Bisulfate | 11 | $92 |
| Atenolol | 20 | $50 |
| Trazodone Hcl | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $253 | $4,29314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Superior
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
- Michael BrennerSouth Sioux City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.